Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963795 | 0.74 | EGFR (0.51) | BRAFRAF1MAP4K4EGFRCSF1R | |
| SCHEMBL5554548 | 0.73 | EGFR (0.43) | BRAFRAF1EGFRCSF1RMEN1 | |
| SCHEMBL5554550 | 0.73 | EGFR (0.43) | BRAFRAF1EGFRCSF1RMEN1 | |
| SCHEMBL6302372 | 0.73 | EGFR (0.65) | BRAFRAF1MAP4K4EGFRCSF1R | |
| SCHEMBL22165293 | 0.73 | KDR (0.63) | EGFRCSF1RTRPA1KDR | |
| SCHEMBL4965096 | 0.72 | IP6K1 (0.54) | BRAFRAF1CSF1RKMT2AIP6K1 | |
| SCHEMBL4965087 | 0.72 | IP6K1 (0.54) | BRAFRAF1CSF1RKMT2AIP6K1 | |
| SCHEMBL3979754 | 0.72 | EGFR (0.69) | BRAFRAF1EGFRCSF1RMEN1 | |
| SCHEMBL21023525 | 0.72 | ALDH1A1 (0.53) | KMT2ALMNATSHRDRD1ALDH1A1 | |
| SCHEMBL25960701 | 0.72 | ALDH1A1 (0.53) | KMT2ALMNATSHRDRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867201-B2 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER INC (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1396489-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | Pfizer Products Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1029853-B1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-6465449-B1 | SUCH AS (6-(4-(6-AMINO-3-AZA-BICYCLO(3.1.0)HEX-3-YLMETHYL)-PHENYL)-QUINAZOLIN-4-YL) -(4-PHENOXY-PHENYL)-AMINE | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1029853-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | RCC1, CCNA1, MCL1 | BRAF 1218/4885RAF1 596/4885MAP4K4 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.